The Human Frontier Science Program (HFSP) is unique in supporting international collaboration to undertake innovative, risky, basic research at the frontier of t [...] Canadian Institutes of Health Research|Government of Canada

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The pl...

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Impact Award supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from the real-world environment, to foster clinical applicability. The Impact Award intends to translate the fundamental understanding of underlying mechanisms toward solutions that have the potential for major near-term impact for patients and clear alignment to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals.Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI’s organization will submit a pre-application, but al...

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Inte...

Background The FDA Oncology Center of Excellence (OCE) aims to advance the development and regulation of oncology products for patients with cancer. The Pediatric Oncology Program and Rare Cancers Program were established to facilitate and expedite drug development for pediatric and other rare cancers. OCE’s Project Catalyst connects scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation, which is particularly important to address the challenges related to product development for ultra-rare cancers. In collaboration with the National Institutes of Health (NIH) and the OCE, the Foundation for the National Institutes of Health (FNIH) recently launched the design phase of the Ultra-Rare Cancer Treatment Advancement Program (ULTRA), a...

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can be deployed to targeted populations at the appropriate time. In order to meet this intent, the mechanism supports health services research approaches. Distinctive Features: ·        The HSRA will support health services research approaches that include comparative effectiveness research; implementation of interventions, diagnostics and clinical practices/guidelines; and validation of data science insights. ...

The purpose of this notice of funding opportunity (NOFO) is to foster research that will inform and support the optimization, delivery, sustainability, and effectiveness of empirically-supported practices for addressing the mental health needs of older adults with serious mental illness (SMI). To this end, NIMH seeks applications that propose work that is focused on practice-relevant questions and conducted within and/or across settings where older adults with SMI are likely to be identified as needing care (e.g., primary care and geriatric specialty clinics, assisted living and long-term care facilities, and community centers). Applications may propose research related to adapting, optimizing, and implementing efficacious treatment and services interventions and strategies to improve c...

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.   Distinctive Features: ·       For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Re...

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.Applications must address one of the following focus areas:·        Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.·        Clinical Care: Improving aspects o...

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to...

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the FY26 VRP Focus Areas. The MCRA may not be used to support preclinical research or clinical trials. Distinctive Features: ·        Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resi...

Get up to $1,000 towards the cost of workplace health and safety items. Program objective If you are a small business owner in NSW, the $1,000 SafeWork small business rebate can help you purchase eligible safety items to make your workplace safer for you and your workers, including managing or eliminating hazards and risks that may cause serious injury, illness or death at work. The Small Business Rebate Program only provides rebates for items that are on the approved eligible items list . This means not every workplace health and safety item can be funded through the program. The eligible items list targets serious workplace risks that could cause major injuries or deaths, particularly in high-risk industries. The approved items focus on higher-level safety controls that help remove ha...

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        Early-Career Clinician Investigator: Serves as the Principal Investigator (PI). Includes investigators with clinical duties in the last year of an accredited medical residency or medical fellowship program, or within five years of initiating a faculty appointment. ·        Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer ...

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, includi...

The National Library of Medicine (NLM) seeks applications for innovative research in clinical informatics. The overarching goal of this forthcoming program is to catalyze the development and advancement of novel informatics methodologies that empower clinicians, patients, and the broader public to better understand, manage, and improve health and health care delivery. This NOFO will support research focused on the design, implementation, and evaluation of clinical informatics tools and methods that enable data-driven discovery, promote evidence-based decision-making, and support personalized and precision health care. Emphasis will be placed on domain-independent, scalable, and reusable/reproducible approaches for the discovery, analysis, organization, and management of health-related d...

This Notice of Funding Opportunity (NOFO) encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals and associated services, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The goal of projects supported by this NOFO is to provide research resources that facilitate optimization and enhancement of scientific rigor, transparency, and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Center...

The Office of Population Affairs (OPA) announces the anticipated availability of funds for Fiscal Year (FY) 2027 grants under the authority of Title X of the Public Health Service Act, Section 1001 (42 U.S.C. §300).This notice solicits applications for projects to provide Title X services throughout the 50 United States, District of Columbia, Guam, the Commonwealth of Puerto Rico, the Northern Mariana Islands, the U.S. Virgin Islands, American Samoa, the U.S. Outlaying Islands (Midway, Wake, et al.), the Republic of the Marshall Islands, the Federated State of Micronesia, and the Republic of Palau (hereafter, States). OPA intends to make available approximately up to $257 million for up to 90 grant awards for a period of up to five (5) years. The actual amount available will not be dete...

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials. Distinctive Features: ·        The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. ·       &nb...

The Engineering Biological and Biomedical Systems (EBBS) program expands our understanding of biological and physiological systems, and it helps improve human health. For U.S. leadership in biotechnology, the engineering of biology is required at every scale. Engineering is needed for sensing biomarkers to making proteins to restoring functions of the body. In EBBS, fundamental mechanistic insights are combined with experimental and computational techniques. This approach helps develop platforms, devices, organisms, tissues, and processes that bring new understanding and control of biological functions. EBBS supports studies of mechanisms that drive the behavior of microbial populations and cells, and of therapeutic cells and tissues. This includes discovering the underlying engineering...

This Notice of Funding Opportunity (NOFO) supports applications to develop and conduct investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or dissemination and implementation science clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, dissemination and implementation science clinical trials and/or prevention strategies. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants ...

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (EIRA) supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced mentor. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        Early-Career Investigator: Serves as the principal investigator. Includes investigators possessing a doctoral degree or equivalent with fewer than three years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training. ·        Mentorship: Applications must include at least ...

The purpose of this document is to advise the public that NOAA/NOS/National Centers for Coastal Ocean Science (NCCOS) Competitive Research Program (NCCOS/CRP) [formerly Center for Sponsored Coastal Ocean Research (CSCOR)/Coastal Ocean Program (COP)] is soliciting proposals to drive practical and cost-effective innovations for harmful algal bloom toxin detection in seafood that promotes seafood safety, food security, and the economic success of U.S. seafood industries and their competitiveness in global markets. For this Announcement, proposals will focus on the development and advancement of innovative, efficient, and effective point-of-use harmful algal bloom toxin detection technologies in support of the Nation’s nutritional, cultural, and economic seafood interests, and to reduce cos...

The National Institutes of Health (NIH) seeks to advance its mission by maintaining strong, productive, and secure international research collaborations in support of the NIH mission. The NIH Collaborative International Research Project (Parent Announcement) supports international research collaborations. This opportunity specifically implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime. This structure provides NIH with oversight capacity for international collaborations, and allows NIH to track international funding, as identified in NOT-OD-25-104. This funding opportunity is specifically designed for NIH to support funded international collaborations between a domestic prime organization and foreign organizations. This NOF...

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3.Distinctive Features:·       &nb...

This Notice of Funding Opportunity (NOFO) solicits applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on sustaining operations and maintaining and evolving the scientific relevance of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that will be s...